Design Therapeutics, Inc. — Director's Dealing 2021

Apr 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Design Therapeutics, Inc. (DSGN)
CIK: 0001807120
Period of Report: 2021-03-30

Reporting Person: SR One Capital Fund I Aggregator LP (10% Owner)
Reporting Person: SR ONE CAPITAL PARTNERS I, LP (10% Owner)
Reporting Person: SR ONE CAPITAL MANAGEMENT, LLC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-30	Common Stock	C	4439839	—	Acquired	4439839	Direct
2021-03-30	Common Stock	C	936637	—	Acquired	5376476	Direct
2021-03-30	Common Stock	P	250000	$20.00	Acquired	5626476	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-30	Series A Preferred Stock	$	C	7236938	Disposed		Common Stock (4439839)	Direct
2021-03-30	Series B Preferred Stock	$	C	1526718	Disposed		Common Stock (936637)	Direct

Footnotes

F1: The Series A Preferred Stock and the Series B Preferred Stock were converted into Common Stock on a 1.63-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: The reported securities are held directly by SR One Capital Fund I Aggregator, LP. SR One Capital Partners I, LP is the general partner of SR One Capital Fund I Aggregator, LP, and SR One Capital Management, LLC is the general partner of SR One Capital Partners I, LP. Simeon George, M.D. is the managing member of SR One Capital Management, LLC. Each of SR One Capital Partners I, LP, SR One Capital Management, LLC and Mr. George may each be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.

F3: SR One Capital Fund I Aggregator, LP purchased 250,000 shares of Common Stock of Design Therapeutics, Inc. (the "Issuer") in connection with the Issuer's public offering.